AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and ...
At month 6, the least-squares mean change in A1c levels from baseline was −1.4% (95% CI, −1.5 to −1.3). By month 12, both fasting and postprandial glucose levels decreased following treatment with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results